Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Medicenna Therapeutics Corp. has unveiled promising preclinical data from its BiSKIT and IL-2 Super Agonist programs, showcasing potential breakthroughs in cancer treatment. Their novel therapies, MDNA113 and MDNA11, have demonstrated significant tumor regression and survival benefits in aggressive cancer models, promising hope for millions affected by tumors worldwide.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
